ライフサイエンスコーパス: neoplasm

1 (for example, intraductal papillary mucinous neoplasms).

2 n age, 69 years; 64.1% male; 44.7% had prior neoplasms).

3 f immune cell responses directed against the neoplasm.

4 e B-cell neoplasms are the fifth most common neoplasm.

5 a highly immunosuppressive and heterogenous neoplasm.

6 luate a pediatric patient with a known liver neoplasm.

7 agnoses include fibroblastic and histiocytic neoplasm.

8 mportant indicator of underlying hematologic neoplasm.

9 with a benign or malignant right-sided colon neoplasm.

10 a clinically diagnosed malignant intraocular neoplasm.

11 (OMM) is the most common canine melanocytic neoplasm.

12 be easily misdiagnosed as malignant hepatic neoplasm.

13 ocytic leukemia (T-PLL) is a poor-prognostic neoplasm.

14 positive donors without active infections or neoplasm.

15 rneal dystrophy or degeneration, and corneal neoplasm.

16 cer (SCLC) is a highly aggressive and lethal neoplasm.

17 osis are complications of myeloproliferative neoplasms.

18 ations and interpretation of pediatric liver neoplasms.

19 zation (WHO) classification of hematopoietic neoplasms.

20 cision medicine techniques to hematolymphoid neoplasms.

21 interest in extending this approach to other neoplasms.

22 1/14 to 9/19 for 405 FN, excluding oncocytic neoplasms.

23 relevance of these signatures in pancreatic neoplasms.

24 (PTCLs) are a heterogeneous group of orphan neoplasms.

25 applications for the treatment of malignant neoplasms.

26 genotypic-phenotypic correlation in ovarian neoplasms.

27 myeloid cancer, and 10% (N = 80) plasma cell neoplasms.

28 rmline mutations are common in many of these neoplasms.

29 s of morphologically challenging intraocular neoplasms.

30 mutations such as histiocytoses and myeloid neoplasms.

31 e most common primary non-glial intracranial neoplasms.

32 wn as one of the most devastating and deadly neoplasms.

33 nt stratification for these rare hematologic neoplasms.

34 lar event associated with myeloproliferative neoplasms.

35 transcription factor TLX3 to cause lymphoid neoplasms.

36 se against recurring pathogens and malignant neoplasms.

37 However, such tumors can be independent neoplasms.

38 , vascular disorders, cardiac disorders, and neoplasms.

39 ards other infectious diseases and malignant neoplasms.

40 declined for lung and other tobacco-related neoplasms.

41 and potential therapeutic approach for these neoplasms.

42 with moderate risk of brain tumors and other neoplasms.

43 eria for the development of multiple primary neoplasms.

44 n exon 9 are prevalent in myeloproliferative neoplasms.

45 e treatment for patients with neuroendocrine neoplasms.

46 better outcomes for patients with pancreatic neoplasms.

47 mic and nonsyndromic) and melanocytic ocular neoplasms.

48 e role of vitamin D in a number of different neoplasms.

49 is upregulated in a large fraction of human neoplasms.

50 on, similar to other intraocular melanocytic neoplasms.

51 tions in association with many hematological neoplasms.

52 a common approach in advanced neuroendocrine neoplasms.

53 s a vital role in the survival and growth of neoplasms.

54 of hyperproliferative pathologies, including neoplasms.

55 role of the E3 ligase FBXW7 in mature B-cell neoplasms.

56 mediastinal GCTs rather than de novo myeloid neoplasms.

57 ng subunits are also observed in endometrial neoplasms.

58 ssible therapeutic avenue for MEN-associated neoplasms.

59 exploited for the treatment of KRAS-mutated neoplasms.

60 alterations found in other pancreatobiliary neoplasms.

61 tients with multiple types of neuroendocrine neoplasms.

62 nditions are considered inflammatory myeloid neoplasms.

63 body-based cancer therapy of ROR2-expressing neoplasms.

64 in fecal samples from patients with advanced neoplasms.

65 (31% versus 92%, P = 0.004) and hematologic neoplasms (23% versus 77%, P = 0.02).

66 teins (31% vs. 92%, P=0.004) and hematologic neoplasms (23% vs. 77%, P=0.02).

67 169 PCLs (90 intraductal papillary mucinous neoplasms, 43 mucinous cystic neoplasms, and 36 non-muci

68 diovascular disease; 5,777 (17%) were due to neoplasms; 5,683 (17%) were due to external causes; 3,15

69 Positive predictive values (PPVs) for any neoplasm 6 mm or greater, advanced neoplasia, and CRC fo

70 patients had died of metastases or secondary neoplasms, 81% were alive, and 14% were lost to follow-u

71 atin regulators are common among mesenchymal neoplasms, a collection of more than 160 tumour types in

72 small number of specific subsequent primary neoplasms account for a large percentage of the total ex

73 Evolving neoplasms accumulate non-synonymous mutations at a high

74 a notable proportion of the excess number of neoplasms across all AYA groups investigated.

75 ence of specific types of subsequent primary neoplasm after each type of AYA cancer.

76 s on the risk of specific subsequent primary neoplasms after 16 types of AYA cancer: breast; cervical

77 ted the risks of specific subsequent primary neoplasms after each of 16 types of AYA cancer.

78 uring molecular analysis of a nonhematologic neoplasm, after hematopoietic cell transplantation, or a

79 especially SM with an associated hematologic neoplasm (AHN).

80 r patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic.

81 to better characterize the genomics of Spitz neoplasms and assess whether the integration of genomic

82 role of TET enzymes in lymphoid and myeloid neoplasms and highlight the importance of metabolic alte

83 RCC at a curable stage result in many benign neoplasms and indolent cancers being resected without cl

84 predominantly intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, while pancreati

85 efractory or recurrent RMS and perhaps other neoplasms and other cancer as well.

86 diting approaches to modify the epigenome of neoplasms and other disease models towards a more 'norma

87 lthy subjects, intraductal papillary mucosal neoplasms and pancreatic ductal adenocarcinoma including

88 sessed during the characterization of B cell neoplasms and stratification of patients with distinct c

89 es in the 2017 WHO classification of myeloid neoplasms and the importance of NPM1 mutations in defini

90 tokeratin staining in the ciliary epithelial neoplasms and the variable Lin28A staining in malignant

91 PGNMID are often associated with hematologic neoplasms and varied prognosis.

92 powerful new vaccine strategy to an array of neoplasms and viral and bacterial pathogens.

93 FL represents ~5% of all haematological neoplasms and ~20-25% of all new non-Hodgkin lymphoma di

94 cases are associated with myeloproliferative neoplasms and/or myelodysplastic syndromes.

95 tumours, and other pulmonary neuroendocrine neoplasms) and a COVID-19 diagnosis, either laboratory c

96 llary mucinous neoplasms, 43 mucinous cystic neoplasms, and 36 non-mucinous cysts) from patients unde

97 mmatory bowel disease and myeloproliferative neoplasms, and numerous ongoing clinical trials in other

98 lesions, new findings in premalignant cystic neoplasms, and recently updated staging criteria for inv

99 rtance of SOX18 etiological role in vascular neoplasms, and suggests R(+)-propranolol repurposing to

100 .8%) benign neoplasms, five (3.4%) malignant neoplasms, and two (1.4%) isolated p53 signature lesions

101 Histiocytic neoplasms are a heterogeneous group of clonal haematopoi

102 has not been reported, although plasma cell neoplasms are a rare form of posttransplant lymphoprolif

103 ely, these data demonstrate that histiocytic neoplasms are characterized by a notable dependence on M

104 Biliary mucinous cystic neoplasms are rare cystic lesions of the liver which car

105 E ADVICE 8: The target detectable pancreatic neoplasms are resectable stage I pancreatic ductal adeno

106 Mature B-cell neoplasms are the fifth most common neoplasm.

107 hepatocellular carcinoma (HCC) because this neoplasm arises, in most cases, in patients with cirrhos

108 Multiple myeloma (MM) is a plasma cell neoplasm associated with a broad variety of genetic lesi

109 a hybrid nerve sheath tumors (N/S HNSTs) are neoplasms associated with larger nerves that occur spora

110 y detected in intraductal papillary mucinous neoplasm-associated PDACs.

111 competing risks ("cumulative incidence") of neoplasms (benign and malignant) and standardized incide

112 ment of the arterial system, lung perfusion, neoplasm, bowel diseases, renal calculi, tumor response

113 Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer tha

114 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematologic malignancy w

115 atopoietic stem cell (HSC) disorder, PV is a neoplasm but its driver mutations result in overproducti

116 sociated with the occurrence of a variety of neoplasms, but the underlying mechanisms have not been d

117 n overlap myeloproliferative/myelodysplastic neoplasm by the World Health Organization and shares som

118 ours and lung metastasis from extrapulmonary neoplasms by contributing to inflammation, angiogenesis,

119 d, mainly in the treatment of neuroendocrine neoplasms by using (177)Lu-labeled somatostatin analogs

120 Moreover, these neoplasms cause significant disease and economic burden

121 Polycythaemia vera is a myeloproliferative neoplasm characterised by excessive proliferation of ery

122 etrating naevi, a type of human pre-melanoma neoplasm characterized by a combined activation of beta-

123 stinal stromal tumor (GIST) is a mesenchymal neoplasm characterized by activating mutations in the re

124 Myelofibrosis is a severe myeloproliferative neoplasm characterized by increased numbers of abnormal

125 Multiple myeloma is a plasma cell neoplasm characterized by the production of unfolded imm

126 ic neuroendocrine tumors are relatively rare neoplasms, characterized by a propensity to secrete horm

127 nd 17-mug Hb/g stool) for detecting advanced neoplasms (colorectal cancer or advanced adenoma).

128 ratin 20-positive, high-grade neuroendocrine neoplasm consistent with Merkel cell carcinoma (MCC).

129 (n = 39) and individuals without colorectal neoplasms (controls, n = 39).

130 immunochemical tests for detecting advanced neoplasms could be increased by acetylsalicylic acid (as

131 of resected cystic pancreatic neuroendocrine neoplasms (cPanNENs) and identify preoperative predictor

132 eristics of cystic pancreatic neuroendocrine neoplasms (cPanNENs) are largely unknown, and their clin

133 d a model to identify patients with advanced neoplasms (CRCs or AAs) based on their miRNA profiles, u

134 e eyelid is an extremely rare but aggressive neoplasm diagnosed primarily in elderly men.

135 Neoplasm diagnoses were confirmed by review of pathology

136 We calculated the age at first neoplasm diagnosis (systematically ascertained cancers p

137 f patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of r

138 Pancreatic and peri-pancreatic neoplasms encompass a variety of histotypes characterize

139 Although evidence for risk of subsequent neoplasm, especially sarcoma and melanoma, was significa

140 iomas (IMs) are the most common intracranial neoplasms, especially in perimenopausal women.

141 For all malignancies and benign tumors ("neoplasms," excluding type Ir pleuropulmonary blastoma a

142 between a chronic inflammatory disease or a neoplasm, exploratory laparotomy was required.

143 f nonproband DICER1 carriers had developed a neoplasm (females, 4.0%; males, 6.6%).

144 nign nonneoplastic results, 10 (6.8%) benign neoplasms, five (3.4%) malignant neoplasms, and two (1.4

145 o the early development of multifocal benign neoplasms followed by their malignant progression.

146 andard care is ablative surgery of malignant neoplasm, followed by tongue reconstruction with free fl

147 tric cumulative incidence curves to estimate neoplasm-free survival.

148 d characterized the genetic features of each neoplasm from a cohort of 15 patients with GCTs and asso

149 The elimination of BRAF and/or NRAS mutated neoplasms from these categories results in the improved

150 he NETest to diagnose gastric neuroendocrine neoplasms (GNENs) and identify micro- and macroscopic re

151 typic, while all 3 patients with hematologic neoplasms had substructure on electron microscopy.

152 requency of Ras mutations in human malignant neoplasms has led to Ras being a desirable chemotherapeu

153 Pancreatic neoplasms have high morbidity and dismal prognosis.

154 lower survival probability, higher grade on neoplasm histology and higher stage on pathology than th

155 rse events (myocarditis, myocardial rupture, neoplasm, hypersensitivity reactions, and immune sensiti

156 Meningiomas are the second most common neoplasm in NF2, often occurring in multiple intracrania

157 with a pathological diagnosis of follicular neoplasm in order to achieve a more conservative managem

158 uded infections in 10 patients and malignant neoplasms in 3 patients.

159 Chest wall neoplasms in children or adolescents are rare.

160 , which represent 10-20% of all intracranial neoplasms in humans.

161 rge percentage of the total excess number of neoplasms in long-term survivors of cervical, breast, an

162 y risk, hazard rates, and the probability of neoplasm incidence accounting for competing risks ("cumu

163 X8 expression is deregulated in a key set of neoplasms, including those arising from the Mullerian du

164 gliomas, papillary thyroid cancers, spitzoid neoplasms, inflammatory myofibroblastic tumors, and acut

165 antle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1 rearrangement with 2

166 molecular radionuclide imaging of pancreatic neoplasms into mainstream clinical practice.

167 Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas and bile duct contain

168 resection for intraductal papillary mucinous neoplasm (IPMN).

169 NET, n = 42), intraductal papillary mucinous neoplasms (IPMN, n = 20), and ampulla of Vater carcinoma

170 Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) a

171 detection of intraductal papillary mucinous neoplasms (IPMNs), and their management remains controve

172 from a chronic inflammatory disease or other neoplasm is only possible by histopathologic examination

173 t of somatic mutations in myeloproliferative neoplasms is dependent on the native cell identity.

174 cinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) are non-invasive neoplasms that are oft

175 ch as the myelodysplastic/myeloproliferative neoplasms (MDS/MPNs).

176 ents with myelodysplastic/myeloproliferative neoplasms (MDSs/MPNs) harbor somatic mutations in myeloi

177 ns of ciliary epithelial and iris epithelial neoplasms, melanocytoma, and melanoma.

178 These categories were followed by neoplasms, mental disorders, and digestive diseases.

179 orthotopic murine pancreatic neuroendocrine neoplasm model expressing human SSTR2.

180 olving from an antecedent myeloproliferative neoplasm (MPN) are characterized by a unique set of cyto

181 ith Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second ca

182 2 signaling is central to myeloproliferative neoplasm (MPN) pathogenesis and results in activation of

183 myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) that leads to progressive bone marrow (BM

184 alling and are drivers of myeloproliferative neoplasm (MPN).

185 as in human "early-stage" myeloproliferative neoplasms (MPN).

186 Myeloproliferative neoplasms (MPNs) are blood cancers that are characterize

187 Ph-negative myeloproliferative neoplasms (MPNs) are hematological cancers that can be s

188 Over 80% of patients with myeloproliferative neoplasms (MPNs) harbor the acquired somatic JAK2 (V617F

189 cogenic driver in several myeloproliferative neoplasms (MPNs), including essential thrombocythemia, m

190 2 inhibitor used to treat myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythem

191 mutations associated with myeloproliferative neoplasms (MPNs).

192 CALR) are frequent within myeloproliferative neoplasms (MPNs).

193 n patients with JAK2V617F myeloproliferative neoplasms (MPNs).

194 in ~20% of patients with myeloproliferative neoplasms (MPNs).

195 atients with CALR-mutated myeloproliferative neoplasms (MPNs).

196 ered calcium signaling in myeloproliferative neoplasms (MPNs).

197 Neuroendocrine neoplasms (NENs) are rare epithelial tumors with heterog

198 rate grading of patients with neuroendocrine neoplasms (NENs) is essential for risk stratification an

199 tors (SSTRs) in patients with neuroendocrine neoplasms (NENs) is used for both diagnosis and treatmen

200 herapy (PRRT) of grade 3 (G3) neuroendocrine neoplasms (NENs) with a Ki-67 proliferation index of gre

201 on detection in patients with neuroendocrine neoplasms (NENs).

202 heterogeneous spectrum of low- to high-grade neoplasms occurring during the entire lifespan of patien

203 id cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origin for whic

204 mphangioleiomyomatosis (LAM) is a metastatic neoplasm of reproductive-age women associated with mutat

205 coma in children and represents a high-grade neoplasm of skeletal myoblast-like cells.

206 edullary plasmacytoma (EMP) is a plasma cell neoplasm of soft tissue without bone marrow involvement

207 Intraductal papillary neoplasm of the biliary tract (B-IPN) is a scarcely know

208 Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal cent

209 ccordingly, novel, targeted therapeutics for neoplasms of the CNS, such as immunotherapy with oncolyt

210 Uterine leiomyomata (UL) are the most common neoplasms of the female reproductive tract and primary c

211 subset progress to atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBP) and/o

212 omatostatin receptors on this neuroendocrine neoplasm opened up the opportunity to treat the patient

213 tric patients at risk for developing a liver neoplasm or how best to evaluate a pediatric patient wit

214 survivors at high risk for second malignant neoplasms or cardiac dysfunction and to the American Can

215 e CAD system classified images as containing neoplasms or nondysplastic BE with 89% accuracy, 90% sen

216 ase (PI3K) pathway alterations are common in neoplasms originating from the uterine endometrium.

217 ll tumour (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF

218 CAD delineations of the area of neoplasm overlapped with those from the BE experts in al

219 antly increased risk of subsequent malignant neoplasms, particularly bone and soft tissue sarcomas, u

220 ases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumo

221 efficacy and acceptable safety in a range of neoplasms, particularly in ovarian cancers.

222 oblast differentiation pathways, bone marrow neoplasm pathway, and PTEN/PI3K/AKT pathway.

223 nd Incidental detection of pancreatic cystic neoplasm (PCN) has increased.

224 Pancreatic cystic neoplasms (PCNs) are a highly prevalent disease of the p

225 size category of 15-25-mm pancreatic cystic neoplasms (PCNs) demonstrated the highest (3.1 times) li

226 y ascertained cancers plus DICER1-associated neoplasms pleuropulmonary blastoma, cystic nephroma, and

227 data sets 2-5 were delineated in detail for neoplasm position and extent by multiple experts whose e

228 e (BETi-P/R) in human postmyeloproliferative neoplasm (post-MPN) secondary AML (sAML) cells demonstra

229 st cancer.Keywords: Breast, MR-Spectroscopy, Neoplasms-Primary(C) RSNA, 2020.

230 pendence.(C) RSNA, 2020Keywords: MR-Imaging, Neoplasms-Primary, Observer Performance, Outcomes Analys

231 d with MTV and with IMH.Keywords: Esophagus, Neoplasms-Primary, PET/CT, Tumor Response (C) RSNA, 2020

232 Abdomen/GI, Evidence Based Medicine, Liver, Neoplasms-Primary, Ultrasound-Contrast(C) RSNA, 2020.

233 nts treated with standard of care (malignant neoplasm progression and pneumonia).

234 ause, large intestine perforation, malignant neoplasm progression, and Stevens-Johnson syndrome) and

235 ase, chronic lower respiratory diseases, and neoplasms) recorded in 2006 for 369 census tracts (small

236 e of mental disorder lost fewer years due to neoplasm-related deaths compared with the general popula

237 hormonal factors in the etiology of lymphoid neoplasms remains unclear.

238 sight into the molecular mechanisms of these neoplasms, revolutionizing our approach to their diagnos

239 first quantitative analysis of site-specific neoplasm risk and excess malignancy risk in 102 systemat

240 operative plasma from IPMN and serous cystic neoplasm (SCN) patients in a pancreas resection cohort (

241 provide a real-life picture of serous cystic neoplasms (SCNs) management once a presumptive diagnosis

242 o sign lesion is observed, benign follicular neoplasm should be considered.

243 melanocytoma) and retinal pigment epithelial neoplasms showed negative results for PAX8.

244 HL was among the first systemic neoplasms shown to be curable with radiation therapy and

245 chemotherapy-associated subsequent malignant neoplasm (SMN) risk.

246 ractionation on risk of subsequent malignant neoplasms (SMNs) in the era of reduced-intensity and non

247 cts of cancer therapy), subsequent malignant neoplasms (SMNs), chronic health conditions, and neuroco

248 n knowledge regarding the risk of subsequent neoplasms (SNs) in children with pathogenic neurofibroma

249 (5 or more years from diagnosis), subsequent neoplasms (SNs), and chronic health conditions were eval

250 egrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognost

251 let therapy, depending on myeloproliferative neoplasm subtype and mutational status.

252 tment and prevention of MYC-dependent B-cell neoplasms such as non-Hodgkin lymphoma and multiple myel

253 uctal adenocarcinoma and high-risk precursor neoplasms, such as intraductal papillary mucinous neopla

254 ween peripheral blood cytopenias and myeloid neoplasms-such as myelodysplastic syndrome-is an area of

255 Multiple myeloma (MM) is a plasma cell neoplasm that commonly expresses CD38.

256 ved and in some cases engender a new myeloid neoplasm that is clonally unrelated to the recipient's o

257 Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, au

258 nic T-cell lymphoma (HSTCL) is a rare T-cell neoplasm that most commonly arises from a small subset o

259 arge cell lymphoma (ALCL) is a mature T cell neoplasm that often expresses the CD4+ T cell surface ma

260 Uterine fibroids are hormone-responsive neoplasms that are associated with heavy menstrual bleed

261 ous cystic neoplasms (MCNs) are non-invasive neoplasms that are often observed in association with in

262 isorders are a family of extranodal lymphoid neoplasms that arise from mature postthymic T cells and

263 l PGRB-overexpressing mice developed ovarian neoplasms that were derived from ovarian luteal cells.

264 elodysplastic syndrome or myeloproliferative neoplasm, the presence of therapy-related acute myeloid

265 The rarity of these neoplasms, the limited knowledge of their driving defect

266 om pancreatic intraductal papillary mucinous neoplasms, the monoclonal antibody Das-1 identifies thos

267 eloped severe dysplasia and cystic papillary neoplasms, there existed no apparent phenotypic differen

268 berrant SHH signaling is implicated in other neoplasms, these studies may also have future relevance

269 o be a consistent feature across histiocytic neoplasms, this remains clinically unproven and many of

270 aintenance develop a therapy-related myeloid neoplasm (TMN).

271 d the development of therapy-related myeloid neoplasms (tMNs).

272 tational and antigenic landscape of evolving neoplasms to influence clinical responses to immunothera

273 with biliary obstruction due to a malignant neoplasm treated with a single-type, commercially availa

274 CML), and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) are a group of rar

275 variety of causes (inflammation, infections, neoplasms, vascular and spondylotic diseases).

276 only independent risk factor for an advanced neoplasm was age (odds ratio, 1.072 per year; 95% confid

277 ents comprising different subtypes of B cell neoplasms, we demonstrate that IgCaller identifies both

278 AERs of any subsequent primary neoplasms were 19.5 per 10 000 person-years (95% CI 17.4

279 nt pancreatic intraductal papillary mucinous neoplasms were developed based on logistic regression (L

280 s, IQR 10.5-25.2), 12 321 subsequent primary neoplasms were diagnosed in 11 565 survivors, most frequ

281 Advanced neoplasms were identified in 224 participants (10.5%), i

282 ump ABCB1 is overexpressed in chemoresistant neoplasms where it effluxes various chemotherapeutic age

283 telets from patients with myeloproliferative neoplasms, where TNF-alpha levels are also increased.

284 Small bowel adenocarcinoma (SBA) is a rare neoplasm, which can occur in a sporadic form or can be a

285 ormation of metastatic poorly differentiated neoplasms, which are similar to human gastroesophageal c

286 o elucidate the heterogeneity found in these neoplasms, which can be of use in the clinical setting o

287 Phyllodes tumors (PTs) are rare breast neoplasms, which have little granular data on margins.

288 llary mucinous neoplasms and mucinous cystic neoplasms, while pancreatic intraepithelial neoplasias a

289 ic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course.

290 oma (EpSCC) is a relatively common cutaneous neoplasm with a poor prognosis.

291 Melanoma is an aggressive neoplasm with increasing incidence that is classified by

292 uamous carcinoma (BSC) is an aggressive skin neoplasm with the features of both basal cell carcinoma

293 a (DLBCL) is a highly heterogeneous lymphoid neoplasm with variations in gene expression profiles and

294 a result, in 2016, classification of myeloid neoplasms with germline predisposition for each of these

295 asms, such as intraductal papillary mucinous neoplasms with high-grade dysplasia and some enlarged pa

296 noma is one of the most aggressive malignant neoplasms with poor outcomes.

297 ification and prognostication of melanocytic neoplasms with Spitzoid cytomorphology.

298 urrent literature on biliary mucinous cystic neoplasms, with a particular emphasis on diagnostic inve

299 eurodegenerative disorders, neurotrauma, and neoplasms, with stroke patients representing the largest

300 ASDRs significantly decreased for most neoplasms, with the main exceptions of cancer of the pan